{"schema_version":"1","generated_at":"2026-11-01T03:31:15.387Z","data_as_of":null,"url":"https://www.findmykol.com/kol/arpita-desai","json_url":"https://www.findmykol.com/kol/arpita-desai/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"arpita-desai","name":"Arpita Desai","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of California, San Francisco","institution_url":"https://www.findmykol.com/institution/university-of-california-san-francisco","city":"San Francisco","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1609151125","openalex":"A5029332651"},"summary":"Arpita Desai is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 78 publications with 2,549 citations (h-index 17).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":78,"cited_by_count":2549,"h_index":17,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1609151125","source":"payments"},"prescribing":{"data_year":2023,"areas_total":4,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":61.8,"classes_total":3,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":40.6,"drugs":[{"name":"Inlyta","share_pct":45.5},{"name":"Cabometyx","share_pct":37.5},{"name":"Fotivda","share_pct":17}],"max_beneficiaries":null},{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":15.7,"drugs":[{"name":"Abiraterone Acetate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":20.3,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":20.3,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":11}]},{"area":"Hormonal (systemic)","share_pct":11.5,"classes_total":1,"classes":[{"class":"l-Thyroxine","setting":"prescribed","share_pct":11.5,"drugs":[{"name":"Levothyroxine Sodium","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0","year":2026,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2025-013788","status":"verified"},{"title":"Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.4560","status":"verified"},{"title":"The coming era of nudge drugs for cancer","year":2025,"journal":"Cancer Cell","source_url":"https://doi.org/10.1016/j.ccell.2025.08.004","status":"verified"},{"title":"YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study","year":2025,"journal":"Journal of the National Comprehensive Cancer Network","source_url":"https://doi.org/10.6004/jnccn.2024.7289","status":"verified"},{"title":"Development of a culturally tailored educational tool designed to increase access to somatic testing among Black men with metastatic prostate cancer (mPCa).","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.1591","status":"verified"}],"source":"works"},"similar":[{"name":"Talmadge King","slug":"talmadge-king","institution":"University of California, San Francisco","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/talmadge-king","json_url":"https://www.findmykol.com/kol/talmadge-king/profile.json"},{"name":"Adil Daud","slug":"adil-daud","institution":"University of California, San Francisco","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/adil-daud","json_url":"https://www.findmykol.com/kol/adil-daud/profile.json"},{"name":"Emmanuelle Waubant","slug":"emmanuelle-waubant","institution":"University of California, San Francisco","specialty":"Neurology","url":"https://www.findmykol.com/kol/emmanuelle-waubant","json_url":"https://www.findmykol.com/kol/emmanuelle-waubant/profile.json"},{"name":"Peter Ganz","slug":"peter-ganz","institution":"University of California, San Francisco","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/peter-ganz","json_url":"https://www.findmykol.com/kol/peter-ganz/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}